COMMUNIQUÉS West-GlobeNewswire

Selecta Biosciences to Present at Upcoming Investor Conferences
01/05/2018
WATERTOWN, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB ), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating [...]
VBI Vaccines Announces First Quarter 2018 Financial Results and Provides Corporate Update
01/05/2018
-- Enrollment completed in PROTECT Phase 3 clinical study of Sci-B-Vac ® Hepatitis B Vaccine -- -- Key upcoming milestones in 2018 for lead eVLP vaccine candidates, VBI-1501 for prevention of Congenital Cytomegalovirus [...]
Jounce Therapeutics to Present at Deutsche Bank 43rd Annual Health Care Conference
01/05/2018
CAMBRIDGE, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE ), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers [...]
CymaBay to Report First Quarter 2018 Financial Results on Tuesday, May 8
01/05/2018
NEWARK, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY ), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high [...]
Atara Biotherapeutics Expands Commercial Leadership Team with the Appointment of Manuela Maronati as General Manager, Europe
01/05/2018
SOUTH SAN FRANCISCO, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA ), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with [...]
Delcath Announces Ratio for Reverse Split Authorization
01/05/2018
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company’s Board of [...]
Release date of three-month interim report (Q1) 2018 and audio cast
01/05/2018
On Friday, 4 May 2018, ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) releases its interim report for the three months ended 31 March 2018. ALK will host a meeting for analysts and institutional investors that day at 1.30 [...]
Endonovo Therapeutics Highlights Feasibility Study Results of Its Electroceutical Therapy in Reducing Proteinuria in Chronic Kidney Disease Patients
01/05/2018
Company to Conduct Larger Clinical Study to Evaluate Its Electroceutical™ Therapy in Chronic Kidney Disease LOS ANGELES, CA, May 01, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the [...]
Spark Therapeutics to Host Conference Call on Tuesday, May 8 at 8:30 a.m. ET to Discuss First Quarter Results and Recent Business Highlights
01/05/2018
PHILADELPHIA, May 01, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE ), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on [...]
Kura Oncology to Report First Quarter 2018 Financial Results
01/05/2018
SAN DIEGO, May 01, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA ), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will [...]
Epizyme Announces First Quarter 2018 Financial Reporting Date and Upcoming Conference Call
01/05/2018
First Quarter 2018 Financial Results to be Announced May 8, 2018 Investor Conference Call to be Scheduled for May 17, 2018 to Discuss Updated Interim Data from Tazemetostat Trials CAMBRIDGE, Mass., May 01, 2018 (GLOBE [...]
FDA Releases Theratechnologies from Post-Approval Commitments Related to EGRIFTA® (Tesamorelin for Injection)
01/05/2018
MONTREAL, May 01, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH ) today announced that the Food and Drug Administration (FDA) has released Theratechnologies from post-approval commitments [...]
La FDA dégage Theratechnologies de ses obligations post-approbation en lien avec EGRIFTA(MD) (tésamoréline pour injection)
01/05/2018
MONTRÉAL, 01 mai 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH ) a annoncé aujourd’hui que la Food and Drug Administration (FDA) dégage Theratechnologies de ses obligations post- [...]
KemPharm, Inc. to Report First Quarter 2018 Results
01/05/2018
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for May 10, 2018, 4:30 p.m. ET CORALVILLE, Iowa, May 01, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH ), a specialty pharmaceutical [...]
Genetic Technologies Announces Grant from NHMRC Awarded to University of Melbourne to Substantially Improve Breast Cancer Risk Prediction and Increase Accessibility
01/05/2018
MELBOURNE, Australia, May 01, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (Nasdaq: GENE ) (“Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic [...]
Trading by management and close relations of management
01/05/2018
Read the full announcement in the attached file Attachment 2018_21_Trading_by_management_EN
Shire plc : Rule 2.9 Announcement
01/05/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 1 May 2018 Shire [...]
Motif Bio REVIVE-2 Phase 3 Study Results with Iclaprim Published in Peer-reviewed Journal, Antimicrobial Agents and Chemotherapy
01/05/2018
Iclaprim met the primary endpoint Iclaprim was well tolerated in the study, with no nephrotoxicity observed Additional data from the previously announced results are included in the publication NEW YORK, May 01, 2018 ( [...]
DBV Technologies to Attend Upcoming Investor Conferences
01/05/2018
Montrouge, France, May 1, 2018 DBV Technologies to Attend Upcoming Investor Conferences DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, [...]

Pages